Pfizer's proposed takeover of AstraZeneca will make "almost no difference to the NHS", an expert on cancer treatment has told ITV News.
Dr Karol Sikora of the University of Buckingham said the majority of drug development was now undertaken by academics and smaller biotechnology companies, rather than big pharmaceutical firms.
He also argued that the economies of scale enabled by a merger between the two firms could mean more research funding that would ultimately benefit patients.
This morning Pfizer has "gone hostile", not with a renewed bid but with an appeal made directly to the shareholders of AstraZeneca.
MPs on the business committee are sceptical that AstraZeneca would remain committed to Britain if taken over by US giant Pfizer.